Venous ethanol
Phase 2Small molecule
Venous ethanol is one of 12 small molecule programs targeting Ventricular Tachycardia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Ventricular Tachycardia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Tambocor
AAlvogen Korea
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coreg
Akero TherapeuticsApproved
Calan
VVal Adams
Approved
Mexitil
Boehringer IngelheimApproved
Duragesic
CCephalon
Preclinical
Betapace
LLegacy Health System
Preclinical
Venous ethanol
TThe Methodist Hospital Research Institute
Phase 2
Guideline Directed Medical Therapy
IIRCCS Policlinico S. Donato
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Venous ethanol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details